These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8136412)

  • 1. Carry-over biases in clinical pharmacology.
    Cleophas TJ
    Eur J Clin Chem Clin Biochem; 1993 Dec; 31(12):803-9. PubMed ID: 8136412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carryover bias in clinical investigations.
    Cleophas TJ
    J Clin Pharmacol; 1993 Sep; 33(9):799-804. PubMed ID: 8227475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 4. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 5. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the 'simple carry-over' model useful?
    Senn SJ
    Stat Med; 1992 Apr; 11(6):715-26. PubMed ID: 1594811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of confounding factors on designs for dose-effect relationship estimates.
    Girard P; Laporte-Simitsidis S; Mismetti P; Decousus H; Boissel JP
    Stat Med; 1995 May 15-30; 14(9-10):987-1005; discussion 1007-8. PubMed ID: 7569515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.
    Ebling WF; Levy G
    Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial treatment length optimization with an emphasis on disease progression studies.
    Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2009 Mar; 49(3):323-35. PubMed ID: 19246730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulation for clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance.
    Ishida K; Kayano Y; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2007 Nov; 30(11):2159-62. PubMed ID: 17978492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biases affecting injected doses of an experimental drug during clinical trials.
    Perrottet N; Brunner-Ferber F; Grouzmann E; Spertini F; Biollaz J; Buclin T; Widmer N
    Trials; 2016 Jul; 17(1):321. PubMed ID: 27423899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simulation study comparing designs for dose ranging.
    Sheiner LB; Hashimoto Y; Beal SL
    Stat Med; 1991 Mar; 10(3):303-21. PubMed ID: 2028115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.
    Lesko LJ; Rowland M; Peck CC; Blaschke TF
    Pharm Res; 2000 Nov; 17(11):1335-44. PubMed ID: 11205725
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimation of half-life periods in nonlinear data with fractional polynomials.
    Mayer B; Keller F; Syrovets T; Wittau M
    Stat Methods Med Res; 2016 Oct; 25(5):1791-1803. PubMed ID: 23999890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis combining parallel and crossover trials using generalised estimating equation method.
    Curtin F
    Res Synth Methods; 2017 Sep; 8(3):312-320. PubMed ID: 28585280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology.
    Kenter MJ; Cohen AF
    Br J Clin Pharmacol; 2015 Apr; 79(4):545-7. PubMed ID: 25711949
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A; Walls C; Lener SE; McDonald SA
    Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease.
    Lockwood P; Ewy W; Hermann D; Holford N
    Pharm Res; 2006 Sep; 23(9):2050-9. PubMed ID: 16906456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.